Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
DENMARK, JUN 21 – CagriSema, combining semaglutide and cagrilintide, achieved up to 23% weight loss in adults with obesity and type 2 diabetes, with low discontinuation rates reported in phase 3 trials.
- Novo Nordisk announced mostly mild-to-moderate side effects and beneficial blood sugar outcomes from phase 3 CagriSema trials at the ADA in Chicago on June 22, 2025.
- These announcements followed the REDEFINE 1 and 2 studies, 68-week phase 3 trials evaluating once-weekly CagriSema, a combination of semaglutide and cagrilintide, in adults with overweight or obesity with or without type 2 diabetes.
- The REDEFINE 1 study involved approximately 3,400 participants who did not have diabetes but faced weight-related health issues, whereas REDEFINE 2 included around 1,200 individuals with type 2 diabetes who were treated with either CagriSema or a placebo.
- Participants lost up to 20.4% body weight in REDEFINE 1 and 13.7% in REDEFINE 2, increasing to 22.7% and 15.7% respectively with full treatment adherence, alongside low discontinuation rates of 6%.
- These findings indicate new possibilities for managing obesity and type 2 diabetes, although negative investor reactions led to a drop in Novo Nordisk’s stock price; the company is also planning additional clinical trials and regulatory submissions before the end of the year.
67 Articles
67 Articles
Experimental drug helps patients lose nearly a quarter of body weight in early trials | Fox Wilmington WSFX-TVAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset
NEWYou can now listen to Fox News articles! An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and …
Experimental drug helps patients lose nearly a quarter of body weight in early trials – Democratic Accent
An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion. “Amycretin is the f…
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment Pharmaceutical giant Novo Nordisk has revealed that its latest weight-loss drug, CagriSema, exhibited mostly mild-to-moderate side effects during trials, accompanied by beneficial blood sugar outcomes. Despite these positive results, investor sentiment remained negatively swayed, reflected in the downturn of Novo's share prices after the announcement.Meanwhile, riv…
Coverage Details
Bias Distribution
- 76% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
